| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C40B30-04 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 |
| filingDate |
2008-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2010-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2010516747-A |
| titleOfInvention |
Method for producing a novel reagent mainly composed of IgE |
| abstract |
The present invention relates to protein engineering technology. More particularly, the present invention relates to human IgE antibodies and derivatives thereof that bind to epitope structures with weak immune activity against IgG or IgM. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9457071-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014027626-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9709576-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013528063-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9989538-B2 |
| priorityDate |
2007-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |